This episode reframes dyslipidaemia as a risk state rather than a symptomatic disease. Lipids move constantly through the body as energy, structure, and signal; when their transport and clearance become unbalanced, vascular injury accumulates silently over decades. We explore lipid-lowering therapy as preventive pharmacology at its most powerful—intervening early, acting slowly, and delivering benefit measured in avoided events rather than felt effects.

Key takeaways you’ll build and reuse throughout the series:

* Lipoproteins as transport systems: LDL, HDL, VLDL, and triglycerides understood as traffic patterns, not lab values.

* Atherosclerosis as chronic inflammation: lipid accumulation, endothelial injury, and plaque evolution over time.

* Statins as foundation therapy: pleiotropic effects beyond cholesterol reduction.

* Add-on strategies explained: ezetimibe, PCSK9 inhibitors, fibrates, and omega-based therapies mapped to mechanism.

* Clinical reasoning: primary versus secondary prevention, absolute risk, adherence, and long-term perspective.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe